Related Experiment Video

Updated: Aug 26, 2025

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

6.9K

Illustration: Thromboelastography - A useful tool to monitor COVID-19-associated coagulopathy

Ashwinkumar Vaidya1, Bemma Paonam1, Ganesh Mohan1

  • 1Department of Immunohematology and Blood Transfusion, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India.

Asian Journal of Transfusion Science
|October 6, 2022
PubMed

Insights

This case study shows that a COVID-19 patient with hypercoagulability, diagnosed via TEG, improved with Enoxaparin treatment. Follow-up TEG normalized, and the patient was discharged without thrombotic issues.

Area of Science:

  • Internal Medicine
  • Hematology
  • Infectious Diseases

Background:

  • COVID-19, caused by SARS-CoV-2, presents with diverse clinical manifestations.
  • Systemic hypercoagulation is a recognized characteristic of COVID-19.
  • Hypercoagulability increases the risk of thrombotic complications in COVID-19 patients.

Purpose of the Study:

  • To report a case of COVID-19 with diagnosed hypercoagulability.
  • To evaluate the efficacy of Enoxaparin in managing hypercoagulability in a COVID-19 patient.
  • To assess the utility of TEG in monitoring coagulation status during COVID-19 treatment.

Main Methods:

  • A COVID-19 patient underwent TEG on admission.
  • Hypercoagulability was identified through TEG analysis.
  • The patient was treated with Enoxaparin sodium (6000 IU twice daily).
  • TEG was repeated after 5 days of treatment.

Main Results:

  • Initial TEG revealed hypercoagulability.
  • Enoxaparin treatment led to normalization of coagulation status within 5 days.
  • The patient experienced no thrombotic complications during hospitalization.

Conclusions:

  • TEG is a valuable tool for diagnosing hypercoagulability in COVID-19.
  • Enoxaparin effectively managed hypercoagulability in this COVID-19 case.
  • Prompt diagnosis and treatment of hypercoagulability can prevent thrombotic events in COVID-19.

Keywords:
COVID19CoagulopathyHaemostasisTEG

More Related Videos

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

832
In Vitro Thrombosis Test for Ventricular Assist Devices09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

750

Related Concept Videos

Coagulation01:06

Coagulation

Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
355
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
28
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
36
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.1K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
11.1K